Antibody Elimination by Apheresis in Living Donor Liver Transplant Recipients

: In the present study, we investigated retrospectively the indications and the efficacy of the elimination of preexisting antiallogeneic antibodies in liver transplant recipients. Three patients who were ABO blood type incompatible were subjected to plasmapheresis and double filtration plasmapheres...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic apheresis 2001-12, Vol.5 (6), p.449-454
Main Authors: Kawagishi, Naoki, Ohkohchi, Nobuhiro, Fujimori, Keisei, Orii, Takashi, Koyamada, Nozomi, Kikuchi, Hiroyuki, Sekiguchi, Satoshi, Tsukamoto, Shigeki, Sato, Toshinobu, Satomi, Susumu
Format: Article
Language:English
Subjects:
ABO Blood-Group System - blood
ABO Blood-Group System - immunology
ABO incompatible
Antibodies - blood
Blood Component Removal
Crossmatch
Graft Rejection - prevention & control
Hemodiafiltration
Humans
Liver Transplantation
Living donor
Living Donors
Plasmapheresis
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: In the present study, we investigated retrospectively the indications and the efficacy of the elimination of preexisting antiallogeneic antibodies in liver transplant recipients. Three patients who were ABO blood type incompatible were subjected to plasmapheresis and double filtration plasmapheresis before the living donor liver transplantation (LDLTx), and the titers decreased to less than 8. After transplantation, plasmapheresis was also performed in 3 cases, and continuous hemodiafiltration in 1 case, and in 2 out of these 3 patients acute rejection was recognized. Two patients who were crossmatch positive were subjected to plasmapheresis before transplantation, and the T warm titers were reduced to less than Score 2. These 2 patients had no acute rejections after transplantation. We conclude that in liver transplant patients apheresis is effective to prevent acute rejection induced by preexisting anti‐A and/or anti‐B antibodies and anti‐donor specific antibodies before transplantation, but it is not effective in a patient with accelerated humoral rejection occurring after transplantation.
ISSN:1091-6660
1526-0968
DOI:10.1046/j.1526-0968.2001.00376.x